In NSCLC, a systematic analysis involving 23 studies evaluated patients who received ICIs; the overall incidence of irAEs was 64% with PD-1 and 66% with PD-L1 inhibitors. This evidence concerns the gene CD274 and non-small cell lung carcinoma.